Search Results - Nolte, Melinda E.

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas

    Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas by Patel‐Hett, Sunita, Martin, Erika J., Mohammed, Bassem M., Rakhe, Swapnil, Sun, Pengling, Barrett, John C., Nolte, Melinda E., Kuhn, Janice, Pittman, Debra D., Murphy, John E., Brophy, Donald F.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    An in vitro pharmacodynamic spiking study of befovacimab, a tissue factor pathway inhibitor monoclonal antibody, in blood samples from patients with severe FVIII deficiency

    An in vitro pharmacodynamic spiking study of befovacimab, a tissue factor pathway inhibitor monoclonal antibody, in blood samples from patients with severe FVIII deficiency by Martin, Erika J., Nolte, Melinda E., Kuhn, Janice, Schmidt, Nicole, Pfaff, Nils, Brophy, Donald F.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Evaluating the thrombin generation profiles of four different rFVIII products in FVIII‐deficient plasma using FIXa and FXIa activation

    Evaluating the thrombin generation profiles of four different rFVIII products in FVIII‐deficient plasma using FIXa and FXIa activation by Brophy, Donald F., Martin, Erika J., Ninivaggi, Marisa, Mohammed, Bassem M., Barrett, John C., Kuhn, Janice, Nolte, Melinda E., Waters, Emily K., Ezban, Mirella

    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Evaluating the thrombin generation profiles of four different r FV III products in FV III‐deficient plasma using FIX a and FXI a activation

    Evaluating the thrombin generation profiles of four different r FV III products in FV III‐deficient plasma using FIX a and FXI a activation by Brophy, Donald F., Martin, Erika J., Ninivaggi, Marisa, Mohammed, Bassem M., Barrett, John C., Kuhn, Janice, Nolte, Melinda E., Waters, Emily K., Ezban, Mirella

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Monitoring rFVIII Prophylaxis Dosing Using Global Hemostasis Assays

    Monitoring rFVIII Prophylaxis Dosing Using Global Hemostasis Assays by Al Hawaj, Maitham, Martin, Erika J., Venitz, Jürgen, Barrett, J. Christian, Kuhn, Janice G., Nolte, Melinda E., Brophy, Donald F.

    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Differential Dose Dependent Effects of Recombinant FVIIa and Enhanced Activity Analogue (NN1731) on Thrombin Generation, Platelet Function and Clot Structure in Blood from Normal Volunteers and Patients with Factor VIII Deficiency with or without Factor VIII Inhibitor Antibodies

    Differential Dose Dependent Effects of Recombinant FVIIa and Enhanced Activity Analogue (NN1731) on Thrombin Generation, Platelet Function and Clot Structure in Blood from Normal V... by Brophy, Donald F., Martin, Erika J., Nolte, Melinda, Kuhn, Jan G., Reddy, Sashidhar N., Ezban, Mirella, Carr, Marcus E.

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    At 90 Micrograms Per Kilogram, Recombinant Factor VIIa Partially Corrects Abnormal Hemostatic Function in Blood from Factor IX Deficient Patients

    At 90 Micrograms Per Kilogram, Recombinant Factor VIIa Partially Corrects Abnormal Hemostatic Function in Blood from Factor IX Deficient Patients by Carr, Marcus E., Martin, Erika J., Kuhn, Janice G., Nolte, Melinda

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: